Trial reportBlood2013
Deep sequencing of the T-cell receptor repertoire in CD8+ T-large granular lymphocyte leukemia identifies signature landscapes.
Trial report in Blood, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 70 citations in OpenAlex.
- Inborn errors of immunity underlie clonal T cell expansions in large granular lymphocyte leukemia.The Journal of clinical investigation · 2025Article
- T Cell Repertoire Analysis as a Molecular Signature of the Spectrum of T-LGL Lymphoproliferative Disorders: Tracing the Literature.Current issues in molecular biology · 2025Review
- Single-Cell Transcriptomic Analysis of Kaposi Sarcoma.PLoS pathogens · 2025Article
- Deep exploration of the TCR CDR3β repertoire specific for viral CD4 T-cell epitopes inside the circulating T-cell repertoire.Frontiers in immunology · 2025Article
- HSP and CD279 gene expression as candidate biomarkers in symptomatic LGLL patients.Discover oncology · 2024Article
- Human TCR repertoire in cancer.Cancer medicine · 2024Review
- Large Granular Lymphocytic Leukemia: Clinical Features, Molecular Pathogenesis, Diagnosis and Treatment.Cancers · 2024Review
- SOHO State of the Art Updates and Next Questions | New Pathways and New Targets in PTCL: Staying on Target.Clinical lymphoma, myeloma & leukemia · 2023Review
- ITK degradation to block T cell receptor signaling and overcome therapeutic resistance in T cell lymphomas.Cell chemical biology · 2023Article
- All that glitters is not LGL Leukemia.Leukemia · 2022Review
- Article
- Defining TCRγδ lymphoproliferative disorders by combined immunophenotypic and molecular evaluation.Nature communications · 2022Article
- Clonotype pattern in T-cell lymphomas map the cell of origin to immature lymphoid precursors.Blood advances · 2022Article
- Single-cell RNA sequencing coupled to TCR profiling of large granular lymphocyte leukemia T cells.Nature communications · 2022Article
- Single-cell characterization of leukemic and non-leukemic immune repertoires in CD8Nature communications · 2022Article
- STAT3 Role in T-Cell Memory Formation.International journal of molecular sciences · 2022Review
- Identification of novel STAT5B mutations and characterization of TCRβ signatures in CD4+ T-cell large granular lymphocyte leukemia.Blood cancer journal · 2022Article
- Predictive value of TCR Vβ-Jβ profile for adjuvant gefitinib in EGFR mutant NSCLC from ADJUVANT-CTONG 1104 trial.JCI insight · 2022Article
- Review
- TCR β chain-directed bispecific antibodies for the treatment of T cell cancers.Science translational medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 3 countries.
Funding
Abstract
New massively parallel sequencing technology enables, through deep sequencing of rearranged T-cell receptor (TCR) Vβ complementarity-determining region 3 (CDR3) regions, a previously inaccessible level of TCR repertoire analysis. The CDR3 repertoire diversity reflects clonal composition, the potential antigenic recognition spectrum, and the quantity of available T-cell responses. In this context, T-large granular lymphocyte (T-LGL) leukemia is a chronic clonal lymphoproliferation of cytotoxic T cells often associated with autoimmune diseases and various cytopenias. Using CD8(+) T-LGL leukemia as a model disease, we set out to evaluate and compare the TCR deep-sequencing spectra of both patients and healthy controls to better understand how TCR deep sequencing could be used in the diagnosis and monitoring of not only T-LGL leukemia but also reactive processes such as autoimmune disease and infection. Our data demonstrate, with high resolution, significantly decreased diversity of the T-cell repertoire in CD8(+) T-LGL leukemia and suggest that many T-LGL clonotypes may be private to the disease and may not be present in the general public, even at the basal level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.